Swapnil Bhargava - CG Oncology, Chief Officer
| CGON Stock | 34.75 0.65 1.91% |
Executive
Swapnil Bhargava is Chief Officer of CG Oncology, Common
| Phone | 949 409 3700 |
| Web | https://cgoncology.com |
CG Oncology, Management Efficiency
The company has return on total asset (ROA) of (0.157) % which means that it has lost $0.157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1976) %, meaning that it created substantial loss on money invested by shareholders. CG Oncology,'s management efficiency ratios could be used to measure how well CG Oncology, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matt Pye | Patterson UTI Energy | N/A | |
| Gerald Spencer | NRG Energy | 42 | |
| Seth Wexler | Patterson UTI Energy | 52 | |
| Kenneth CPA | Patterson UTI Energy | 64 | |
| Aldo Rodriguez | Drilling Tools International | N/A | |
| Judith Lagano | NRG Energy | 58 | |
| Lindsay Ellis | Kinetik Holdings | N/A | |
| Jameson Parker | Drilling Tools International | N/A | |
| Mark Andrews | Nabors Industries | 51 | |
| Michael JD | NRG Energy | 58 | |
| David Johnson | Drilling Tools International | 59 | |
| Kenneth Pucheu | Patterson UTI Energy | 46 | |
| Diana Dotolo | Patterson UTI Energy | N/A | |
| Brian JD | NRG Energy | 46 | |
| William CFA | Nabors Industries | N/A | |
| Marty Unrein | Patterson UTI Energy | N/A | |
| Veda Ragsdill | Drilling Tools International | N/A | |
| Miguel Sanchez | Nabors Industries | N/A | |
| Rasesh Patel | NRG Energy | 50 | |
| Tom Bullis | Cheniere Energy Partners | N/A | |
| Hilary Ware | Cheniere Energy Partners | N/A | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.16 |
CG Oncology, Common Leadership Team
Elected by the shareholders, the CG Oncology,'s board of directors comprises two types of representatives: CG Oncology, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CGON. The board's role is to monitor CG Oncology,'s management team and ensure that shareholders' interests are well served. CG Oncology,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CG Oncology,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Corleen Roche, CFO Secretary | ||
| Bing Kung, Vice Development | ||
| Joshua Patterson, General Officer | ||
| Ambaw MS, President COO | ||
| Swapnil Bhargava, Chief Officer | ||
| Vijay MD, Chief Officer | ||
| Arthur Kuan, Chairman CEO | ||
| Amy Steele, Accounting Finance |
CGON Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CG Oncology, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (658.02) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 67.63 M | ||||
| Shares Owned By Insiders | 6.95 % | ||||
| Shares Owned By Institutions | 92.27 % | ||||
| Number Of Shares Shorted | 5.4 M | ||||
| Price To Book | 4.30 X | ||||
| Price To Sales | 3,372 X |
Pair Trading with CG Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving against CGON Stock
| 0.46 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.42 | VTRS | Viatris | PairCorr |
| 0.42 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.31 | BCTXW | BriaCell Therapeutics | PairCorr |
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.